JP6280499B2 - Ｆｃ融合タンパク質の精製方法 - Google Patents

Ｆｃ融合タンパク質の精製方法 Download PDF

Info

Publication number
JP6280499B2
JP6280499B2 JP2014519246A JP2014519246A JP6280499B2 JP 6280499 B2 JP6280499 B2 JP 6280499B2 JP 2014519246 A JP2014519246 A JP 2014519246A JP 2014519246 A JP2014519246 A JP 2014519246A JP 6280499 B2 JP6280499 B2 JP 6280499B2
Authority
JP
Japan
Prior art keywords
protein
chromatography
tnfr
elution
resin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014519246A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014520814A5 (OSRAM
JP2014520814A (ja
Inventor
イケチユキユ，イジェオマ・シンシア
ンテイ−ギヤバアー，ジヨセフ
ペトロフ，マシユー
リー，クリステイン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of JP2014520814A publication Critical patent/JP2014520814A/ja
Publication of JP2014520814A5 publication Critical patent/JP2014520814A5/ja
Application granted granted Critical
Publication of JP6280499B2 publication Critical patent/JP6280499B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
JP2014519246A 2011-07-08 2012-07-03 Ｆｃ融合タンパク質の精製方法 Expired - Fee Related JP6280499B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161505710P 2011-07-08 2011-07-08
US61/505,710 2011-07-08
PCT/US2012/045339 WO2013009526A1 (en) 2011-07-08 2012-07-03 Method for purifying fc-fusion protein

Publications (3)

Publication Number Publication Date
JP2014520814A JP2014520814A (ja) 2014-08-25
JP2014520814A5 JP2014520814A5 (OSRAM) 2015-07-30
JP6280499B2 true JP6280499B2 (ja) 2018-02-14

Family

ID=47506409

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014519246A Expired - Fee Related JP6280499B2 (ja) 2011-07-08 2012-07-03 Ｆｃ融合タンパク質の精製方法

Country Status (10)

Country Link
US (1) US9556258B2 (OSRAM)
EP (1) EP2729482B1 (OSRAM)
JP (1) JP6280499B2 (OSRAM)
KR (1) KR20140043934A (OSRAM)
CN (1) CN103814044A (OSRAM)
AU (2) AU2012282960A1 (OSRAM)
BR (1) BR112014000352A2 (OSRAM)
CA (1) CA2840951A1 (OSRAM)
DK (1) DK2729482T3 (OSRAM)
WO (1) WO2013009526A1 (OSRAM)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104010654B (zh) 2011-10-18 2017-10-27 科荣生生物科学公司 金属离子稳定的依那西普制剂
HRP20180182T1 (hr) * 2012-09-11 2018-04-20 Coherus Biosciences, Inc. Pravilno presavijeni etanercept visoke čistoće i izvanrednog prinosa
US20160024144A1 (en) * 2013-03-14 2016-01-28 Amgen Inc. Removal of leaked affinity purification ligand
CA2907771C (en) * 2013-03-26 2023-01-10 Coherus Biosciences, Inc. Perfusion method for manufacturing etanercept
JP6609561B2 (ja) * 2014-02-04 2019-11-20 バイオジェン・エムエイ・インコーポレイテッド 翻訳後修飾を濃縮するための、フロースルーモードにおける陽イオン交換クロマトグラフィーの使用
ES2929099T3 (es) 2014-05-02 2022-11-24 Grace W R & Co Material de soporte funcionalizado y métodos de fabricación y uso de material de soporte funcionalizado
WO2015175679A2 (en) 2014-05-13 2015-11-19 Amgen Inc. Process control systems and methods for use with filters and filtration processes
US10556942B2 (en) 2014-06-13 2020-02-11 Lupin Limited Process for the purification of TNFR:Fc fusion protein
FR3025515B1 (fr) * 2014-09-05 2016-09-09 Lab Francais Du Fractionnement Procede de purification d'un anticorps monoclonal
WO2016065273A1 (en) * 2014-10-24 2016-04-28 The University Of Chicago Heat-inducible self-assembling protein domains
US20160130324A1 (en) 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
MX394035B (es) * 2014-12-31 2025-03-21 Lg Chemical Ltd Procedimiento para preparar una proteina de fusion tnfr-fc que contiene un contenido objetivo de impurezas.
BR112017026193B1 (pt) * 2015-06-05 2021-09-14 W.R. Grace & Co-Conn Adsorventes, método de produção dos adsorventes e uso dos adsorventes
EP3353288A1 (en) 2015-09-22 2018-08-01 H. Hoffnabb-La Roche Ag Expression of fc-containing proteins
US20170101435A1 (en) * 2015-10-13 2017-04-13 Therapeutic Proteins International, LLC Harvesting and perfusion apparatus
CN108463243B (zh) 2015-11-19 2022-06-14 夏尔人类遗传性治疗公司 重组人c1酯酶抑制剂及其用途
CN109071613A (zh) 2016-05-11 2018-12-21 通用电气医疗集团生物工艺研发股份公司 分离基质
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
JP7106187B2 (ja) 2016-05-11 2022-07-26 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックスを保存する方法
WO2017194593A1 (en) 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Method of cleaning and/or sanitizing a separation matrix
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
WO2018018011A2 (en) 2016-07-22 2018-01-25 Amgen Inc. Methods of purifying fc-containing proteins
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
CN109929038B (zh) * 2017-12-15 2020-10-09 山东博安生物技术有限公司 Vegf捕获剂融合蛋白的纯化方法
CN109929027B (zh) * 2017-12-15 2020-10-09 山东博安生物技术有限公司 采用线性洗脱步骤的重组融合蛋白纯化方法
EP4671268A2 (en) * 2019-03-21 2025-12-31 Lonza Sales AG METHOD FOR PREPARING EXTRACELLULAR VESICLES
IL292940A (en) * 2019-11-22 2022-07-01 Morphosys Ag Eluate collection during antibody chromatography
EP4142792A4 (en) 2020-05-01 2024-11-27 Kashiv Biosciences, LLC An improved process of purification of protein
US11416468B2 (en) * 2020-07-21 2022-08-16 International Business Machines Corporation Active-active system index management
CN112574321B (zh) * 2020-12-30 2023-10-20 上海赛金生物医药有限公司 一种捕获单克隆抗体-肿瘤坏死因子融合蛋白的亲和纯化方法
WO2022174114A1 (en) * 2021-02-11 2022-08-18 Denali Therapeutics Inc. Anti-transferrin receptor fusion proteins and methods of use thereof
CA3233422A1 (en) * 2021-09-28 2023-04-06 Kashiv Biosciences, Llc An improved process for purification of fusion protein
CA3233420A1 (en) * 2021-09-28 2023-04-06 Kashiv Biosciences, Llc An improved process of purification of fusion protein
CN114891061A (zh) * 2022-04-25 2022-08-12 杭州艾策生物技术有限公司 一种糖基化重组蛋白的纯化方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998031806A2 (en) * 1997-01-21 1998-07-23 Human Genome Sciences, Inc. Fc RECEPTORS AND POLYPEPTIDES
EP1006183A1 (en) * 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
EP1463942B2 (en) 2001-12-21 2012-06-20 Immunex Corporation Methods for purifying protein
ES2285188T3 (es) * 2002-07-15 2007-11-16 Immunex Corporation Metodo y medios para controlar sialilacion de proteinas producidas por celulas de mamifero.
GB0304576D0 (en) * 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
ATE462716T1 (de) 2003-10-24 2010-04-15 Amgen Inc Verfahren zur aufreinigung von proteinen in einer durchflussfraktion aus der chromatographie mit hydrophoben wechselwirkungen
CN1946739A (zh) * 2004-04-14 2007-04-11 豪夫迈－罗氏公司 纯化的白细胞介素－15/Fc融合蛋白及其制备
ZA200900836B (en) 2006-08-28 2010-05-26 Ares Trading Sa Process for the purification of FC-fusion proteins
JP2010501622A (ja) * 2006-08-28 2010-01-21 アレス トレーディング ソシエテ アノニム Ｆｃ−融合タンパク質の精製法
WO2008085988A1 (en) * 2007-01-05 2008-07-17 Amgen Inc. Methods of purifying proteins
CN102187227B (zh) * 2008-09-15 2014-04-02 Emd密理博公司 定量蛋白质系亲和色谱树脂的蛋白质泄露的方法
US20120282654A1 (en) 2009-04-29 2012-11-08 Schering Corporation Antibody purification
KR101415660B1 (ko) * 2009-08-07 2014-07-16 이엠디 밀리포어 코포레이션 샘플 중의 1 이상의 불순물로부터 표적 단백질을 정제하는 방법
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production

Also Published As

Publication number Publication date
AU2012282960A1 (en) 2014-01-16
EP2729482B1 (en) 2018-03-07
US9556258B2 (en) 2017-01-31
EP2729482A1 (en) 2014-05-14
DK2729482T3 (en) 2018-05-07
CN103814044A (zh) 2014-05-21
WO2013009526A1 (en) 2013-01-17
US20140187751A1 (en) 2014-07-03
JP2014520814A (ja) 2014-08-25
EP2729482A4 (en) 2015-02-25
CA2840951A1 (en) 2013-01-17
BR112014000352A2 (pt) 2017-02-14
KR20140043934A (ko) 2014-04-11
AU2017204893A1 (en) 2017-08-03

Similar Documents

Publication Publication Date Title
JP6280499B2 (ja) Ｆｃ融合タンパク質の精製方法
US11459374B2 (en) Anti-VEGF protein compositions and methods for producing the same
US20220289832A1 (en) Protein purification
US20140288278A1 (en) Chromatography process for resolving heterogeneous antibody aggregates
TW201444863A (zh) 增加蛋白質之焦－麩胺酸形成的方法
CA3214610A1 (en) Purification of antibodies by mixed mode chromatography
Grzeskowiak 2-D DIGE to facilitate downstream process development for recombinant therapeutic antibodies
HK1184467A (en) Protein purification

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150612

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160531

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170818

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171226

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180119

R150 Certificate of patent or registration of utility model

Ref document number: 6280499

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees